,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,CLDN18,SFTPJ,ENSG00000066405,Claudin 18,3,137998735-138033655,Predicted membrane proteins,Evidence at protein level,"CAB013010, CAB013243, HPA018446",Enhanced,,,,,Group enriched,Group enriched,85,lung: 361.8;stomach: 689.7,heart muscle: 6.1,Not detected,,
1,GAGE2E,GAGE8,ENSG00000275113,G antigen 2E,X,49341192-49345922,Predicted intracellular proteins,Evidence at transcript level,HPA043232,Approved,,Uncertain,Golgi apparatus<br>Plasma membrane<br>Cytosol,,Not detected,Group enriched,60,stomach: 15.4;testis: 8.6,small intestine: 0.2,Group enriched,5.0,AN3-CA: 943.7;K-562: 455.5;T-47d: 231.8
2,DAZ4,,ENSG00000205916,Deleted in azoospermia 4,Y,24833843-24907040,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA047113,Approved,,,,,Not detected,Group enriched,40,stomach: 22.3;testis: 21.5,skin: 0.5,Group enriched,123.0,U-266/70: 117.1;U-266/84: 107.2
3,TFF2,SML1,ENSG00000160181,Trefoil factor 2,21,42346357-42351128,"Cancer-related genes, Predicted secreted proteins",Evidence at protein level,"CAB025834, HPA036705",Enhanced,,,,Liver cancer:1.99e-4 (unfavourable),Group enriched,Group enriched,29,duodenum: 1027.1;stomach: 5110.7,gallbladder: 107.1,Group enriched,20.0,CAPAN-2: 32.8;PC-3: 124.0
4,DAZ2,"MGC126442, pDP1678",ENSG00000205944,Deleted in azoospermia 2,Y,23219434-23291356,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA047113,Approved,,,,,Not detected,Group enriched,27,stomach: 15.5;testis: 7.2,skin: 0.4,Cell line enriched,9.0,SK-MEL-30: 1.4
5,NKX6-2,"GTX, NKX6.1, NKX6B",ENSG00000148826,NK6 homeobox 2,10,132783179-132786052,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,,,,,,,Tissue enriched,Group enriched,25,cerebral cortex: 15.7;stomach: 16.7,testis: 0.6,Not detected,,
6,MUC6,,ENSG00000184956,"Mucin 6, oligomeric mucus/gel-forming",11,1012821-1036706,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,CAB002165,Enhanced,,,,,Tissue enhanced,Group enriched,24,duodenum: 15.4;seminal vesicle: 40.2;stomach: 24.0,epididymis: 1.1,Not detected,,
7,C6orf58,LEG1,ENSG00000184530,Chromosome 6 open reading frame 58,6,127519455-127591817,Predicted secreted proteins,Evidence at protein level,"HPA036263, HPA041449",Enhanced,,,,,Group enriched,Group enriched,21,duodenum: 603.5;salivary gland: 163.4;stomach: 314.9,esophagus: 17.1,Cell line enhanced,,RPMI-8226: 1.8;WM-115: 1.8
8,TAAR1,"TA1, TAR1, TRAR1",ENSG00000146399,Trace amine associated receptor 1,6,132644984-132646003,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,HPA055614,Approved,,,,,Tissue enhanced,Group enriched,17,fallopian tube: 2.2;stomach: 7.8,"duodenum,endometrium,prostate,urinary bladder: 0.2",Not detected,,
9,CCKBR,,ENSG00000110148,Cholecystokinin B receptor,11,6259736-6272127,"Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,13,cerebral cortex: 13.6;pancreas: 5.4;stomach: 16.4,prostate: 0.9,Cell line enriched,8.0,NTERA-2: 69.8
10,FUT9,Fuc-TIX,ENSG00000172461,Fucosyltransferase 9,6,96015984-96215612,Predicted membrane proteins,Evidence at protein level,HPA070923,,,Approved,Nucleoplasm<br>Microtubules<br>Cytokinetic bridge<br>Cytosol,,Tissue enhanced,Group enriched,12,cerebral cortex: 28.1;stomach: 22.4,duodenum: 2.0,Cell line enhanced,,MCF7: 2.2;RT4: 5.1;SCLC-21H: 7.5;SK-BR-3: 2.7
11,CHIA,"AMCase, CHIT2, TSA1902",ENSG00000134216,"Chitinase, acidic",1,111290862-111320566,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA059193,Approved,,,,,Tissue enhanced,Group enriched,11,lung: 15.6;stomach: 8.2,endometrium: 1.1,Cell line enhanced,,ASC diff: 1.1
12,CYP2C18,"CPCI, CYP2C, CYP2C17, P450IIC17",ENSG00000108242,Cytochrome P450 family 2 subfamily C member 18,10,94683621-94736190,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,11,duodenum: 103.1;esophagus: 24.6;gallbladder: 24.5;liver: 97.8;small intestine: 88.1;stomach: 62.2,tonsil: 6.2,Cell line enhanced,,BEWO: 3.0
13,CCKAR,,ENSG00000163394,Cholecystokinin A receptor,4,26481400-26490462,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Group enriched,10,gallbladder: 47.2;stomach: 15.2,tonsil: 3.1,Not detected,,
14,VSIG1,MGC44287,ENSG00000101842,V-set and immunoglobulin domain containing 1,X,108044970-108079184,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA001445, HPA036310, HPA036311",Enhanced,,Approved,Vesicles<br>Cytosol,,Group enriched,Group enriched,10,stomach: 185.7;testis: 91.1,gallbladder: 14.3,Cell line enhanced,,HBEC3-KT: 2.5;HUVEC TERT2: 5.9;PC-3: 2.2
15,COL2A1,"AOM, SEDC, STL1",ENSG00000139219,Collagen type II alpha 1 chain,12,47972965-48004486,"Cancer-related genes, Disease related genes, Predicted secreted proteins",Evidence at protein level,"CAB002214, HPA055753",Supported,,Approved,Nucleoplasm,,Mixed,Group enriched,9,epididymis: 23.0;stomach: 6.2,prostate: 1.6,Group enriched,23.0,AF22: 154.1;HAP1: 101.9;HEK93: 33.7
16,CTSE,,ENSG00000196188,Cathepsin E,1,206009264-206023909,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA012940, CAB032687",Enhanced,,,,Urothelial cancer:5.26e-5 (favourable),Group enriched,Group enriched,9,duodenum: 229.1;stomach: 1121.8,lung: 74.6,Group enriched,7.0,BEWO: 20.3;RT4: 32.6
17,NTS,,ENSG00000133636,Neurotensin,12,85874295-85882992,Predicted secreted proteins,Evidence at protein level,HPA026664,Enhanced,,,,"Cervical cancer:9.94e-5 (favourable), Endometrial cancer:5.10e-4 (unfavourable)",Tissue enhanced,Group enriched,9,small intestine: 189.6;stomach: 43.5,lymph node: 13.4,Cell line enhanced,,HEL: 45.5;NTERA-2: 10.8
18,AQP5,,ENSG00000161798,Aquaporin 5,12,49961870-49965681,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA065008,Enhanced,,Approved,Plasma membrane,Head and neck cancer:1.75e-5 (favourable),Tissue enhanced,Group enriched,8,salivary gland: 255.6;stomach: 53.3;testis: 176.4,breast: 21.1,Group enriched,9.0,CAPAN-2: 7.6;REH: 9.2
19,FAM159B,,ENSG00000145642,Family with sequence similarity 159 member B,5,64690308-64718090,Predicted membrane proteins,Evidence at protein level,HPA011778,Enhanced,,,,,Tissue enriched,Group enriched,8,pancreas: 1.0;stomach: 3.4,"cerebral cortex,duodenum: 0.2",Group enriched,17.0,NTERA-2: 3.5;RPTEC TERT1: 5.5;SCLC-21H: 1.5
20,PSCA,,ENSG00000167653,Prostate stem cell antigen,8,142670308-142682724,"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA030783, HPA056418",Approved,,Supported,Plasma membrane,Pancreatic cancer:5.60e-5 (unfavourable),Tissue enriched,Group enriched,8,prostate: 344.6;stomach: 1648.5;urinary bladder: 343.4,esophagus: 101.7,Cell line enhanced,,CAPAN-2: 18.6;HeLa: 27.5;RT4: 47.1
21,ALDH3A1,ALDH3,ENSG00000108602,Aldehyde dehydrogenase 3 family member A1,17,19737984-19748943,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB045957, HPA051150, HPA063783",Enhanced,,Enhanced,Vesicles<br>Plasma membrane<br>Cytosol,Head and neck cancer:7.55e-5 (favourable),Mixed,Group enriched,7,esophagus: 406.1;skin: 84.3;stomach: 207.2,tonsil: 31.0,Cell line enriched,21.0,A549: 4306.9
22,EPS8L3,"FLJ21522, MGC16817",ENSG00000198758,EPS8 like 3,1,109750080-109764027,Predicted intracellular proteins,Evidence at protein level,HPA030998,Approved,,Approved,Vesicles,"Renal cancer:2.52e-5 (unfavourable), Liver cancer:4.13e-5 (unfavourable), Urothelial cancer:1.82e-4 (favourable)",Group enriched,Group enriched,7,colon: 75.0;duodenum: 152.1;gallbladder: 59.8;rectum: 86.1;small intestine: 167.1;stomach: 53.4,appendix: 15.1,Group enriched,12.0,CACO-2: 13.3;CAPAN-2: 13.3;EFO-21: 5.8;Hep G2: 25.0
23,ERN2,IRE1b,ENSG00000134398,Endoplasmic reticulum to nucleus signaling 2,16,23690326-23713500,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA016558,Uncertain,,,,,Mixed,Group enriched,7,"cervix, uterine: 27.6;colon: 27.5;duodenum: 12.3;gallbladder: 25.1;rectum: 23.2;small intestine: 9.9;stomach: 49.1",appendix: 3.8,Cell line enriched,8.0,CAPAN-2: 5.9
24,ESRRB,"DFNB35, ERR2, ERRb, ERRbeta, ESRL2, NR3B2",ENSG00000119715,Estrogen related receptor beta,14,76310614-76501841,"Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors",Evidence at protein level,,,,,,,Mixed,Group enriched,7,heart muscle: 2.3;kidney: 5.2;skeletal muscle: 1.7;stomach: 1.5;testis: 1.4,breast: 0.3,Cell line enhanced,,HMC-1: 1.0;K-562: 3.3;U-266/70: 1.2
25,PAX6,"AN, AN2, D11S812E, WAGR",ENSG00000007372,Paired box 6,11,31784779-31818062,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors",Evidence at protein level,"HPA030775, CAB034143",Supported,,Enhanced,Nucleoplasm,,Tissue enhanced,Group enriched,7,cerebral cortex: 22.3;stomach: 11.2,testis: 2.5,Cell line enhanced,,AF22: 15.6;AN3-CA: 19.1;HEK93: 17.3;U-251 MG: 14.4
26,PSAPL1,,ENSG00000178597,Prosaposin-like 1 (gene/pseudogene),4,7430294-7434973,Predicted secreted proteins,Evidence at protein level,"HPA038013, HPA038482",Approved,,Enhanced,Cytosol,,Mixed,Group enriched,7,skin: 52.7;stomach: 36.5,breast: 6.4,Cell line enhanced,,CACO-2: 13.5;HaCaT: 3.9;hTCEpi: 3.9;RPMI-8226: 16.8
27,C2orf70,LOC339778,ENSG00000173557,Chromosome 2 open reading frame 70,2,26562582-26579532,Predicted intracellular proteins,Evidence at protein level,HPA062453,Enhanced,,Approved,Nuclear membrane<br>Vesicles,Pancreatic cancer:6.49e-4 (favourable),Mixed,Group enriched,6,fallopian tube: 12.0;stomach: 4.9;testis: 17.5,thyroid gland: 1.9,Cell line enhanced,,A-431: 3.6;CAPAN-2: 2.7;EFO-21: 1.8;RPTEC TERT1: 2.8
28,HNF4A,"HNF4, MODY, MODY1, NR2A1, TCF14",ENSG00000101076,Hepatocyte nuclear factor 4 alpha,20,44355700-44434596,"Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA004712, CAB019417",Enhanced,,Supported,Nucleoplasm,,Tissue enhanced,Group enriched,6,colon: 58.0;duodenum: 103.0;kidney: 44.7;liver: 51.0;rectum: 47.8;small intestine: 90.9;stomach: 21.9,gallbladder: 9.2,Group enriched,8.0,CACO-2: 126.0;Hep G2: 77.0
29,IGFALS,ALS,ENSG00000099769,Insulin like growth factor binding protein acid labile subunit,16,1790413-1794971,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA040692, HPA040948",Approved,,Supported,Nucleoplasm,"Liver cancer:5.97e-4 (favourable), Endometrial cancer:6.06e-4 (unfavourable)",Tissue enhanced,Group enriched,6,liver: 25.0;stomach: 6.6,gallbladder: 2.5,Cell line enhanced,,Hep G2: 1.2;U-266/70: 1.3
30,IHH,"BDA1, HHG2",ENSG00000163501,Indian hedgehog,2,219054420-219060467,"Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Endometrial cancer:3.67e-6 (favourable),Tissue enhanced,Group enriched,6,"cervix, uterine: 8.9;colon: 21.0;duodenum: 14.9;endometrium: 31.4;rectum: 16.7;small intestine: 16.5;stomach: 15.3",prostate: 3.2,Cell line enriched,11.0,CACO-2: 16.8
31,SDR16C5,"EPHD-2, RDH-E2, RDHE2",ENSG00000170786,Short chain dehydrogenase/reductase family 16C member 5,8,56300010-56320776,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA025224,Enhanced,,,,Head and neck cancer:7.88e-4 (favourable),Mixed,Group enriched,6,breast: 15.2;esophagus: 36.3;lung: 40.3;skin: 72.9;small intestine: 21.7;stomach: 21.0;tonsil: 25.3,"cervix, uterine: 5.6",Cell line enhanced,,CAPAN-2: 22.6;HaCaT: 11.3;hTCEpi: 15.1;T-47d: 9.2
32,SOX21,SOX25,ENSG00000125285,SRY-box 21,13,94709622-94712399,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,"HPA048337, HPA064084",Approved,,Approved,Nucleus,"Glioma:1.34e-4 (favourable), Cervical cancer:7.60e-4 (favourable)",Tissue enhanced,Group enriched,6,cerebral cortex: 17.9;esophagus: 6.9;skin: 19.4;stomach: 33.4,tonsil: 3.1,Cell line enhanced,,AF22: 80.6;HAP1: 12.8;NTERA-2: 22.0;PC-3: 11.6
33,TPH1,"TPH, TPRH",ENSG00000129167,Tryptophan hydroxylase 1,11,18017564-18042426,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB010767, HPA022483",Enhanced,,Uncertain,Cytosol,,Mixed,Group enriched,6,colon: 8.8;duodenum: 10.2;rectum: 21.0;small intestine: 12.6;stomach: 15.5,prostate: 2.4,Mixed,,
34,TRIM31,"C6orf13, HCG1, HCGI, RNF",ENSG00000204616,Tripartite motif containing 31,6,30102897-30113106,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA046400,Uncertain,,,,,Group enriched,Group enriched,6,colon: 10.0;small intestine: 2.3;stomach: 2.1;urinary bladder: 2.7,duodenum: 0.7,Cell line enriched,527.0,RT4: 232.7
35,ACER2,"ALKCDase2, ASAH3L, FLJ41587",ENSG00000177076,Alkaline ceramidase 2,9,19409059-19452020,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,5,placenta: 14.8;stomach: 62.9;urinary bladder: 44.1,skin: 7.6,Group enriched,5.0,BEWO: 30.0;RT4: 62.6
36,AKR1C2,"BABP, DD, DD2, DDH2, HAKRD, MCDR2, TDD",ENSG00000151632,Aldo-keto reductase family 1 member C2,10,4987400-5018031,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB047304, HPA068265",Enhanced,,Approved,Nucleus<br>Nucleoli fibrillar center<br>Endoplasmic reticulum<br>Cytosol,,Group enriched,Group enriched,5,adipose tissue: 330.4;breast: 105.2;esophagus: 94.9;gallbladder: 151.9;liver: 161.4;stomach: 126.5;urinary bladder: 143.0,duodenum: 29.8,Cell line enhanced,,A549: 1864.0;ASC diff: 1674.9;Hep G2: 2661.0;RT4: 940.6
37,AKR7A3,,ENSG00000162482,Aldo-keto reductase family 7 member A3,1,19282558-19289250,Predicted intracellular proteins,Evidence at protein level,HPA064638,,,Approved,Cytosol,Renal cancer:8.80e-7 (favourable),Group enriched,Group enriched,5,duodenum: 170.4;gallbladder: 38.7;kidney: 49.0;liver: 44.8;small intestine: 106.8;stomach: 70.3,colon: 15.9,Cell line enhanced,,SK-BR-3: 12.6
38,FER1L6,C8ORFK23,ENSG00000214814,Fer-1 like family member 6,8,123851987-124120061,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA054117,Uncertain,,,,,Group enriched,Group enriched,5,rectum: 12.0;stomach: 42.4,small intestine: 5.1,Cell line enhanced,,AF22: 1.0;ASC TERT1: 1.3;BJ hTERT+: 1.0;PC-3: 1.6;U-87 MG: 1.6
39,FOXA3,HNF3G,ENSG00000170608,Forkhead box A3,19,45863989-45873797,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB015154, HPA054034",Uncertain,,Approved,Nucleoplasm,,Mixed,Group enriched,5,colon: 16.7;duodenum: 10.3;liver: 32.5;pancreas: 9.8;rectum: 17.9;small intestine: 13.9;stomach: 33.8,gallbladder: 3.6,Cell line enhanced,,CACO-2: 8.4;HDLM-2: 11.2;Hep G2: 18.9;K-562: 20.1;NTERA-2: 10.8
40,ISL1,"Isl-1, ISLET1",ENSG00000016082,ISL LIM homeobox 1,5,51383391-51394738,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA057416,Approved,,Enhanced,Nucleoplasm,,Tissue enhanced,Group enriched,5,placenta: 10.7;prostate: 15.5;seminal vesicle: 25.9;stomach: 9.8,testis: 2.9,Cell line enriched,14.0,SH-SY5Y: 307.2
41,LRRC31,FLJ23259,ENSG00000114248,Leucine rich repeat containing 31,3,169839179-169869930,Predicted intracellular proteins,Evidence at protein level,HPA037548,Uncertain,,,,,Mixed,Group enriched,5,colon: 18.2;duodenum: 8.8;rectum: 24.3;small intestine: 11.0;stomach: 9.8,liver: 2.8,Cell line enhanced,,EFO-21: 1.8;HAP1: 1.4;RPTEC TERT1: 1.6
42,MYEOV,OCIM,ENSG00000172927,Myeloma overexpressed,11,69294138-69367726,Predicted membrane proteins,Evidence at transcript level,HPA012949,Uncertain,,Approved,Nucleus<br>Vesicles,"Pancreatic cancer:1.54e-7 (unfavourable), Renal cancer:1.48e-5 (unfavourable), Lung cancer:2.00e-4 (unfavourable)",Mixed,Group enriched,5,adipose tissue: 4.0;breast: 5.8;esophagus: 9.2;skin: 1.8;stomach: 6.8,appendix: 1.0,Cell line enhanced,,A-431: 154.1;A549: 74.9;U-2 OS: 38.7
43,NPAS1,"bHLHe11, MOP5, PASD5",ENSG00000130751,Neuronal PAS domain protein 1,19,47019820-47045775,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA043364, HPA072259",,Approved,Approved,Nucleoplasm,,Tissue enhanced,Group enriched,5,cerebral cortex: 3.9;skin: 4.4;spleen: 1.8;stomach: 2.6,lymph node: 0.6,Cell line enhanced,,HEK93: 10.1;NB-4: 11.4
44,SLC26A9,,ENSG00000174502,Solute carrier family 26 member 9,1,205913048-205943460,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA051485,Enhanced,,Approved,Nucleus<br>Cell Junctions,Head and neck cancer:8.55e-5 (favourable),Tissue enhanced,Group enriched,5,lung: 11.4;salivary gland: 31.5;stomach: 30.8,tonsil: 4.8,Group enriched,12.0,CAPAN-2: 11.8;Hep G2: 3.4
45,SULT1B1,ST1B2,ENSG00000173597,Sulfotransferase family 1B member 1,4,69721162-69787961,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA002107,Enhanced,,Approved,Nucleoplasm<br>Golgi apparatus,,Group enriched,Group enriched,5,colon: 68.9;duodenum: 99.0;rectum: 67.1;small intestine: 103.7;stomach: 41.6,appendix: 13.8,Group enriched,6.0,HUVEC TERT2: 92.0;TIME: 29.6;U-2197: 29.2
